Nuvectis Pharma (NVCT) Retained Earnings (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Retained Earnings data on file, last reported at -$105.7 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 34.52% year-over-year to -$105.7 million; the trailing twelve-month figure through Mar 2026 stood at -$105.7 million (down 34.52% YoY), and the FY2025 full-year result was $118.1 million, up 261.24% from the prior year.
• Retained Earnings declined to -$105.7 million in Q1 2026, from $118.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $118.1 million in Q4 2025 to a low of -$105.7 million in Q1 2026.
• A 5-year average of -$27.3 million and a median of -$41.7 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings plunged 1790.54% in 2022 and surged 301.22% in 2024, its largest moves.
• Tracing NVCT's Retained Earnings over 5 years: stood at -$32.0 million in 2022, then slumped by 69.6% to -$54.2 million in 2023, then sank by 35.03% to -$73.2 million in 2024, then surged by 261.24% to $118.1 million in 2025, then sank by 189.5% to -$105.7 million in 2026.
• Business Quant data shows NVCT's Retained Earnings at -$105.7 million in Q1 2026, $118.1 million in Q4 2025, and -$92.4 million in Q3 2025.